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Abstract
Aim There is accumulating evidence that neutropenic patients require higher dosages of vancomycin. To prevent sub-therapeutic
drug exposure, it is of utmost importance to obtain adequate exposure from the first dose onwards. We aimed to quantify the
effect of neutropenia on the pharmacokinetics of vancomycin.
Methods Data were extracted from a matched patient cohort of patients known with (1) hematological disease, (2)
solid malignancy, and (3) patients not known with cancer. Pharmacokinetic analysis was performed using non-linear
mixed effects modeling with neutropenia investigated as a binary covariate on clearance and volume of distribution
of vancomycin.
Results A total of 116 patients were included (39 hematologic patients, 39 solid tumor patients, and 38 patients not known with
cancer). In total, 742 paired time-concentration observations were available for the pharmacokinetic analysis. Presence of
neutropenia showed to significantly (p = 0.00157) increase the clearance of vancomycin by 27.7% (95% CI 10.2–46.2%),
whereas it did not impact the volume of distribution (p = 0.704).
Conclusions This study shows that vancomycin clearance is increased in patients with neutropenia by 27.7%. Therefore, the
vancomycin maintenance dose should be pragmatically increased by 25% in neutropenic patients at the start of treatment. Since
the volume of distribution appeared unaffected, no adjustment in loading dose is required. These dose adjustments do not rule out
the necessity of further dose individualization by means of therapeutic drug monitoring.
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Introduction
Vancomycin is an effective antibiotic agent with antimicrobial
activity against infections caused by gram-positive bacteria,
including methicillin-resistant Staphylococcus aureus.
Vancomycin is frequently used to treat potential infections in
febrile neutropenic patients with hematological disease [1, 2].
For an effective treatment, it is important to quickly reach
therapeutic plasma concentrations of vancomycin that is guid-
ed using therapeutic drug monitoring. Current international
guidelines recommend a target range for the trough concen-
tration of 15–20 mg/L for intermittent infusion schedules,
which in daily practice can be achieved with a vancomycin
dose of 15–20mg/kg given every 8–12 h inmost patients with
normal renal function [3]. Interestingly, patients with hemato-
logical malignancies appear to require much higher dosages of
vancomycin than patients not known with malignant disease
in order to achieve therapeutic plasma concentrations [4, 5].
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This difference is likely due to an increased clearance of van-
comycin in this specific patient population. Specifically, re-
cent studies show that especially neutropenia is a risk factor
associated with the increased clearance of vancomycin [6–8].
Patients with hematological malignancies are often neutro-
penic due to the disease or during and after chemotherapeutic
treatment of the disease. Febrile neutropenia is strongly asso-
ciated with an increased mortality risk with a mortality rate in
severe septic patients of up to 40–50% [9, 10]. Furthermore, it
is associated with increased health care costs [11, 12].
Thereby, it is of utmost importance to obtain adequate antibi-
otic drug exposure from the first dose onwards, with as little as
dose titration necessary, especially in this vulnerable group of
patients. Using the current standard vancomycin
dosingdosage regimen, therapeutic plasma concentrations
are often reached late in neutropenic patients with hematolog-
ical malignancies, as dose requirements are often higher than
initially prescribed. Only a minority of hematologic cancer
patients reaches therapeutic plasma concentrations following
standard dosingdosage regimens [4, 5, 13–15]. Nonetheless,
despite this knowledge of the augmented clearance and neces-
sity for higher vancomycin dosages, the effect of neutropenia
on the clearance of vancomycin has thus far not yet properly
been quantified, hampering a proper dose advice.
Quantification of the effect of neutropenia on the pharmaco-
kinetics of vancomycin allows the development of an effective
dosage regimen for this specific patient population. However,
in most studies thus far conducted, hematological disease and/
or cancer—and not specifically neutropenia—was taken as
covariate for estimation of the altered vancomycin pharmaco-
kinetics. As a result, the available effect size estimations on
clearance and volume of distribution of vancomycin are not
consistent and vary widely among studies. Therefore, the aim
of this study was to properly quantify the effect of neutropenia
on the pharmacokinetics of vancomycin using non-linear
mixed effect modeling.
Patients and methods
Study design and patient population
The primary objective of the study was to quantify the effect of
neutropenia on the pharmacokinetics of vancomycin. To be able
to compare the pharmacokinetics of vancomycin between vari-
ous patient populations, a retrospective, matched cohort design
was used consisting of three cohorts of patients, i.e., patients
with (1) hematologicaldisease, (2) solid tumor, and (3) patients
not known with cancer. The flowchart of the inclusion of pa-
tients is provided in Fig. 1. Patients were matched on age, gen-
der, and year of treatment. Inclusion criteria were age 18 years or
older, treatment with intravenous vancomycin therapy for ≥
2 days due to bacteriologically documented or suspected
gram-positive infections, plus at least one available vancomycin
plasma concentration. Patients who had received a single dose
of vancomycin and patients on dialysis were excluded. Patient
and treatment characteristics were retrospectively collected by
analysis of the Electronic Healthcare Record System and by the
use of the Santeon Farmadatabase. The study was approved by
the medical ethical committee of the Catharina Hospital
Eindhoven and was conducted following the principles of the
Declaration of Helsinki.
Patient and treatment characteristics
The following baseline patient and treatment characteristics
were obtained: underlying malignant diagnosis, age, gender,
height, total body weight (TBW), aspartate aminotransferase
(AST), alanine amino transferase (ALT), serum creatinine, white
blood cell count (WBC), absolute neutrophil count, C-reactive
protein (CRP), albumin, and type of chemotherapy. Creatinine
clearance was calculated according to the Cockcroft-Gault for-
mula [16]. All variables were registered as the last known value
within 7 days before the start of the vancomycin therapy; for the
ANC, values within 2 days of the start of treatment were also
accepted in case no baseline values were available. Except for
albumin, and CRP, for which a time window of 2 weeks and
3 days was maintained, respectively. Current chemotherapy was
registered as yes or no for the malignancy groups. During treat-
ment with vancomycin, all available data on serum creatinine,
white blood cell count, absolute neutrophil count, and C-
reactive proteinwere extracted. Furthermore, loading dose, daily
dose, infusion time, peak serum levels, trough serum levels,
frequency of dosing, dosing interval, dose adjustments, frequen-
cy of dose adjustments, duration of vancomycin therapy, and
time of blood sampling were extracted.
Bioanalysis
Plasma concentrations of vancomycin were measured during
routine clinical care on a Viva-E system, using a validated
spectrophotometric homogeneous enzyme immunoassay
(Emit® 2000, Siemens Healthcare Diagnostics). The calibra-
tion curve ranged from 0 to 50 mg/L. Besides a calibration
curve, quality control samples of known concentrations (7.4,
17.5, and 34.0 mg/L) were incorporated in each run with co-
efficients of variation of 4.2%, 2.4%, and 4.6%, respectively.
Peak plasma concentrations were collected within 30–60 min
after the end of infusion, and trough concentrations immedi-
ately before the next dose.
Pharmacokinetic analysis
Pharmacokinetic model development Pharmacokinetic anal-
ysis was performed by means of non-linear mixed effects
modeling, the software package NONMEM V7.3, with
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Piraña v2.9.4 as an interface for NONMEM, R statistics
v3.4.0 and Perl Speaks Nonmem [17]. Imprecision of param-
eter estimates was calculated with the sampling importance
resampling procedure [18]. Model development was guided
by physiological plausibility and goodness-of-fit, as assessed
with standard goodness-of-fit plots and prediction-corrected
visual predictive checks [19]. Non-nested models were
assessed with the Akaike Information Criterion [20].
The previously developed pharmacokinetic model for van-
comycin by Staatz et al. was used as a starting point of our
analysis [21]. This model described vancomycin pharmacoki-
netics with distribution in one compartment of which the vol-
ume was linearly scaled to total body weight. Clearance of
vancomycin was linearly related to creatinine clearance, as
estimated with the Cockcroft-Gault formula. Lastly, residual
error was described with a combined additive and proportion-
al error, and inter-individual variability was described with an
exponential error. After initial fitting of the model, we
investigated the necessity of model adjustments to better de-
scribe our population. Furthermore, as vancomycin is a known
hydrophilic drug [22], scaling of the volumes of distribution to
total body weight may not be optimal, as it is unlikely that
adipose tissue evenly contributes to distribution vancomycin
as non-adipose tissue. We, therefore, investigated the perfor-
mance scaling of the volume of distribution to normal fat mass
and fat-free mass, as proposed recently [23]. When scaling to
fat-free mass, we scaled the pharmacokinetic parameters to a
mass of 57.2 kg, corresponding to the fat-free mass of a typical
man of 1.80 m and a total body weight of 70 kg.
A posteriori power and covariate analysis Neutropenia was
tested as a covariate for the pharmacokinetics of vancomycin.
Presence of neutropenia was defined as absolute neutrophil
count (ANC) < 1.5 cells/nL. Absence of neutropenia was de-
fined as ANC ≥ 1.5 cells/nL, or in case no differential of the
WBC was available, a normalWBC value defined asWBC >
(1) <18 years old
(1) demographics missing
(2) dialysis 
(3) unreliable serum concentrations 
(4) <2 days vancomycin treatment 
(5) vancomycin treatment in different years* 
(7) no vancomycin levels measured 
matched to control groups based on: 
- gender 
- year of birth 
- year of treatment 
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Fig. 1 Flowchart of the study
4 cells/nL plus no clinical suspicion of neutropenia. During
covariate analysis, statistical significance was calculated from
the decrease in objective function. A decrease of 3.84 points
or more, associated with a p value of < 0.05, was considered
statistically significant. Non-nested models were assessed
with the Akaike Information Criterion. [20] After the devel-
opment of the base model, we investigated the power in to
detect a clinically relevant (defined as a > 33.3%) change in
clearance or total volume of distribution because of neutrope-
nia at a significance level of 5%. For this purpose, we per-
formed a stochastic simulation and estimation study, using the
SSE tool in Perl Speaks Nonmem [17] with 500 virtual studies
for each power calculation. After the power analysis, we in-
vestigated the impact of neutropenia as binary covariate on
clearance and total volume of distribution.
Simulation study With the final model, we performed a sim-
ulation of the pharmacokinetics of vancomycin in an intermit-
tent and continuous dosingdosage regimen of 1800 mg per
24 h in a three times daily intermittent or continuous regimen.
This dose was based on a previously developed and validated
nomogram [24]. Alternate dosing schemes were explored at
the discretion of the investigators to overcome subtherapeutic
exposure.
Results
Patient characteristicsWithin the period of 2010–2016, a total
of 116 matched patients were enrolled in the study, of which
39 patients with a hematologic malignancy, 39 patients with a
solid tumor, and 38 patients not known with cancer. Table 1
shows the patient baseline characteristics and Table 2 shows
the underlying malignancies of the oncologic patients.
Primary diagnoses of the patients with a hematological malig-
nancy was acute myeloid leukemia (59%), Hodgkin’s or non-
Hodgkin’s lymphoma (21%), or other types of leukemia
(21%), of which in total 80% of the patients were on current
chemotherapy schedules. Primary diagnoses of the patients
with solid tumors were gastro-intestinal cancer (72%), uro-
genital cancer (26%), and CNS tumor (3%), of which in total
33% of the patients were on current chemotherapeutic treat-
ment regimens. In a total of 5756 (4948%) patients, ANC
values were known within the specified time frame of 7 days
prior to treatment or within 2 days after the start of treatment.
In another 10 (9%) patients, the WBC was too low (≤ 0.10
cells/nL) in order to determine a differential count, and they
could, therefore, be categorized as neutropenic based on their
lowWBC values. In the remaining 4950 (4243%) patients, no
differential WBC was available. However, in all these pa-
tients, the WBC exceeded the minimum value of 4 cells/nL.
In addition, no neutropenia was suspected from their clinical
presentation and these patients were, therefore, categorized as
non-neutropenic. In total, this resulted in a total of 31 neutro-
penic patients, of which 29 were known with hematological
disease. The median time window between determination of
ANC or white blood cell count and the start of vancomycin
treatment was 0 days (range 0–7 days).
Pharmacokinetic analysis
Pharmacokinetic model development After initial fitting of
the model, we observed under-prediction of vancomycin plas-
ma concentrations at the end of the dosing interval, indicating
the presence of a peripheral distribution compartment.
Estimation of a peripheral compartment significantly
(p < 0.001) improved model fit, and, therefore, this was
retained in the model. Furthermore, when investigating the
impact of body size on the volume of distribution, fat tissue
did not contribute to the distribution of vancomycin (data not
shown) and, therefore, volume of distribution was
allometrically scaled to fat-free mass. This was associated
with a better model fit compared to scaling to total body
weight, observed as decrease of the Akaike Information
Criterion of > 10 points. For the same reason, the inter-
compartmental clearance between the central and peripheral
compartment was allometrically scaled to fat-free mass.
Because clearance of vancomycin was already related to body
weight, with body weight being one of the variables in the
Cockcroft-Gault creatinine clearance equation, clearance was
not additionally scaled to body size for the base model. The
detailed modeling results and parameter estimates for the base
and final model are shown in the supplementary files of this
manuscript.
A posteriori power and covariate analysis We found that in
our population, when using the developed base model, we had
93.8% and 83.4% power to detect a respective change of
33.3% in clearance and total volume due to neutropenia.
When investigating the presence of neutropenia as a covariate
for clearance of vancomycin, we found that neutropenia rele-
vantly and significantly (p = 0.00157) increased clearance in
neutropenic patients by 27.7% (95% confidence interval
10.2–46.2%). The presence of neutropenia did not significant-
ly impact the volume of distribution (p = 0.704) and was,
therefore, not included in the final model.
Simulation study To demonstrate the change in vancomycin
levels between the current dosingdosage regimen and the algo-
rithm obtained with our model, a simulation of the pharmaco-
kinetics of vancomycin was performed for a typical male pa-
tient (70 kg, 1.80 m) with a normal kidney function (creatinine
clearance of 104 ml/min). Following continuous infusion of
1800 mg vancomycin therapeutic levels were reached, while a
neutropenic patient on the same dose reached subtherapeutic
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levels. Increasing the vancomycin dose by 25% showed thera-
peutic levels in the same neutropenic patient. Plots of the van-
comycin levels after continuous infusion in non-neutropenic
and neutropenic patients are shown in Fig. 2 (panel a).
A similar simulation was performed for an intermittent in-
fusion of vancomycin seen in Fig. 2 (panel b). With a dose of
1800 mg vancomycin divided over three administrations re-
sulted in subtherapeutic trough levels in the neutropenic pa-
tient. The non-neutropenic patient showed levels within this
therapeutic range at the same dose. The vancomycin levels
were comparable to the trough levels of the non-neutropenic
patient after increasing the vancomycin dose by 25%.
Discussion
The results of this study show that neutropenia is significantly
associated with a 27.7% higher clearance of vancomycin.
Thereby, as the systemic exposure is directly proportional to
drug dose, the vancomycin maintenance dose should be prag-
matically increased by 25% at the start of therapy in neutro-
penic patients with hematological diseases, followed by fur-
ther therapeutic drug monitoring. Because in our study, neu-
tropenia appeared not to affect volume of distribution; no in-
crease in the loading dose seems required. Increasing the van-
comycin maintenance dose immediately at the start of therapy
Table 1 Patient characteristics
Characteristic Total (n = 116) Hematological malignancy (n = 39) Solid tumor (n = 39) Non-cancer (n = 38) sP
Sex, N (%) 0.97
Male 67 (58%) 22 (56%) 23 (59%) 22 (58%)
Female 49 (42%) 17 (44%) 16 (41%) 16 (42%)
Age 0.23
(years) mean ± SD 61.4 ± 13.4 59.7 ± 15.6 64.4 ± 10.5 60.1 ± 13.4
BMI 0.002
median (IQR) 25.5 (5.9) 24.0 (6.2) 26.9 (6.2) 26.3 (7.2)
WBC (cells/nL) < 0.001
median (IQR) 8.4 (13.5) 0.5 (4.6) 10.7 (7.4) 11.7 (8.6)
ANC (cells/nL)# < 0.001
median (IQR) 4.2 (9.9) 0.11 (2.2) 6.8 (4.9) 11.0 (4.4)
AST (U/L) 0.06
median (IQR) 28.0 (29.0) 25.5 (35.5) 34.0 (30.5) 29.5 (35.5)
ALT (U/L) 0.20
median (IQR) 28.5 (34.0) 23.0 (29.5) 28.0 (29.5) 34.0 (34.0)
Albumin (g/L) 0.001
median (IQR) 31.0 (10.0) 35.0 (4.0) 25.5 (11.0) 32.0 (13.0)
ln Cockcroft-Gault clearance (ml/min) 0.07
median (IQR) 4.53 (.69) 4.71 (.73) 4.37 (.60) 4.52 (.60)
C-reactive protein (mg/L) 0.07
median (IQR) 150 (134) 150 (141) 200 (140) 120 (117)
# In 10 patients, no differential was performed due to lowWBC (WBC ≤ 0.1 cells/nL) and are therefore not included in the calculation of the median and
IQR
ALT, alanine aminotransferase; ANC, absolute neutrophile count; AST, aspartate aminotransferase; BMI, body mass index; IQR, interquartile range; ln,
natural logarithm; WBC, white blood cell count
Table 2 Underlying malignancy
Hematological malignancy (n = 39) Solid tumor (n = 39)
Underlying malignancy (N)* AML (23) Gastrointestinal cancer (28)
HL /NHL (8) Urogenital cancer (7)
ALL (2) Breast cancer (3)
Other (6) CNS malignancy (1)
Chemotherapy
Yes (%) 80% 33%
No (%) 20% 67%
ALL, acute lymphoblastic leukemia; AML, acute myelocytic leukemia; HL/NHL, Hodgkin’s/hon-Hodgkin’s
lymphoma
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may prevent unnecessary subtherapeutic drug exposure, less
dose titration after initiation of therapy, and may, thereby, in-
crease effectiveness of treatment. This is of special importance
in neutropenic patients with hematological disease, as these
patients are often immunocompromised, and S. aureus infec-
tions are associated with high mortality rates of up to 40–50%
[9, 10].
Our findings confirm the earlier exploratory study by
Haeseker et al. who also revealed neutropenia as principal
independent predictor of clearance as well as the study by
Choi et al. who showed the association between neutropenia
and subtherapeutic levels of vancomycin [6, 7]. Similarly,
Fernandez de Gatta et al. and Normand et al. found an
increased clearance in neutropenic patients [4, 15].
Noteworthy, our study took into account all multiple peak
and trough concentrations during the complete course of treat-
ment with vancomycin. This is contrary to the study of Le
Normand et al., where multiple blood samples were analyzed
around a single vancomycin administration and Fernandez de
Gatta et al. [4, 15], who measured serum vancomycin concen-
tration only after the initial dose and at steady state. The con-
tribution of our study to current literature is the development
of a pharmacokinetic model of vancomycin in neutropenic
and non-neutropenic patients. This allowed quantitative as-
sessment of the effect of neutropenia on vancomycin clear-
ance. Furthermore, in clinical practice, this model can serve as
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Fig. 2 Simulation study results.
Panel a Comparison of
vancomycin levels after
continuous infusion in a
nonneutropenic patient (1800 mg/
day) and in a neutropenic patient
(1800 mg/day and 2250 mg/day).
Panel b Comparison of
vancomycin levels after
intermittent infusion in a non-
neutropenic patient with a dosage
of 1800 mg/day (600 mg TID*)
and in a neutropenic patient with a
dosage of 1800 mg/day (600 mg
TID) and 2250 mg/day (750 mg
TID). The shaded areas represent
the therapeutic ranges. *TID,
three times daily
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a useful tool to guide vancomycin dose individualization by
means of therapeutic drug monitoring in both patient groups.
This study may have been limited by its retrospective na-
ture, with potential variation in exact administration times of
vancomycin and timing of blood collection for determination
of vancomycin peak and trough levels. However, on the other
hand, it may be considered a strength being a real-world study
in a daily patient population. Although the influence of neu-
tropenia is evident, the underlying mechanism of augmented
clearance in neutropenic patients is still not completely under-
stood. It is therefore an interesting topic for future research.
Physiological processes that are altered during febrile illness
may play a role in changed pharmacokinetics. Renal
hyperfiltration is considered as a possible mechanism to explain
the reduced vancomycin levels in critically ill patients. This
phenomenon might develop from a hyperdynamic circulation
as a response to systemic inflammation and is associated with
elevated renal perfusion [25, 26]. However, as calculated creat-
inine clearance was an inherent part of the pharmacokinetic
model, we postulate that in our analysis, potential
hyperfiltration is already accounted for. Another hypothesis
may be that serum albumin concentrations affect the observed
vancomycin pharmacokinetics. Vancomycin is known to bind
to serum albumin [27] and, therefore, decreased serum albumin
concentrations may result in lower total (bound and unbound)
vancomycin concentrations. Notably, serum albumin concen-
trations in the patients with hematological malignancies, i.e.,
most patients with neutropenia, were not different in compari-
son to non-cancer patients, as presented in Table 1 (off note, the
significant difference in albumin levels in Table 1 is driven by
the lower albumin levels in solid tumor patients). Therefore,
variations in serum albumin concentrations seem an unlikely
cause for the augmented clearance of vancomycin. Therefore,
until the mechanism is unraveled, neutropenia should be con-
sidered a risk factor for decreased vancomycin exposure.
This study was not designed to investigate the effect of a
higher maintenance dosage on mortality, costs, and overall
outcome. In order to study the effect of the adjusted dosage
regimen on outcome, a prospective study in hematologic pa-
tients with neutropenia comparing the standard maintenance
dosage with a 25% higher dosage is necessary. Increased plas-
ma concentrations of vancomycin are associated with in-
creased risk of nephrotoxicity [3]. However, increasing the
maintenance dose in neutropenic patients by 25% to reach
therapeutic plasma concentrations is not likely to increase
the risk of nephrotoxicity, as the data show that thereby no
supratherapeutic—but therapeutic—plasma concentrations
will be reached.
Lastly, it is unknown whether our results may be extrapo-
lated to all neutropenic patients, as the majority of the neutro-
penia cases were in patients with hematological malignancy.
Further studies in a more diverse patient group may help to
answer this question.
To conclude, this study shows that neutropenia is associat-
ed with increased clearance of vancomycin. We suggest to
pragmatically increase the initial vancomycin dose by 25%
in this vulnerable patient population with neutropenia to in-
crease the likelihood of pharmacokinetic target attainment,
along with therapeutic drug monitoring to further tailor the
dose of vancomycin.
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